Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t

Abstract

Ustekinumab has the highest confounder-corrected long-term drug survival in psoriasis treatment, compared with adalimumab and etanercept. Higher BMI is a predictor for discontinuation due to ineffectiveness in etanercept and ustekinumab, and female sex is a consistent predictor for discontinuation due to side-effects in all three outpatient biologics.

Earlier discontinuation of TNF‐α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects

“…These results are consistent with observations in psoriasis patients in which cessation of adalimumab therapy because of side effect was also associated with female sex . In psoriasis discontinuation rates of adalimumab and infliximab therapy were significantly higher for women than for men . Our finding that anti‐TNFs are more often discontinued in female patients may not be unique, since also in psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis, female sex has been identified as a risk factor for TNF‐α inhibitor therapy cessation .…”

“…Sex may be such a patient‐specific factor. Female sec has been associated with lower drug persistence of TNF‐α inhibitor therapy in psoriasis, psoriatic arthritis and rheumatoid arthritis . In CD an association between female sex and discontinuation of adalimumab has been reported .…”

Predictors of drug survival for tumour necrosis factor-α and interleukin 12/23 antagonists in psoriasis

“…In this issue of the BJD , Zweegers et al . report data from one academic and eight nonacademic centres in the Netherlands, using a Dutch psoriasis biologics register (BioCAPTURE).…”

Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE

“…reported lower survival rates for biologics than the survival rates for MTX in our study. For instance, the median drug survival for adalimumab ranges between approximately 1·7 and 4·9 years, between 1·2 and 3·6 years for etanercept and between 1·7 and 3·7 years for infliximab . MTX is also used in rheumatoid arthritis.…”

“…In addition, we considered short treatment discontinuations < 90 days as continuous treatment. This is an arbitrary but widely accepted interruption time for a systemic therapy . The strengths of our study include the detailed data regarding patients, treatment characteristics, side‐effects and effectiveness.…”